» Articles » PMID: 34668234

Long Bone Fractures in Fibrous Dysplasia/McCune-Albright Syndrome: Prevalence, Natural History, and Risk Factors

Overview
Date 2021 Oct 20
PMID 34668234
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is a rare bone and endocrine disorder arising along a broad spectrum. Long-bone fractures are a common, painful, and potentially disabling complication. However, fracture prevalence and risk factors have not been well-established, making it difficult to predict which patients are at risk for a severe course. Clinical and imaging data were reviewed from two large, well-phenotyped cohorts (National Institutes of Health [NIH] in the United States and the Leiden University Medical Center [LUMC] in the Netherlands) to identify long-bone fractures at FD sites. Skeletal burden score was quantified using bone scintigraphy. Multiple linear regressions were performed to identify clinical associations with fractures. A total of 419 patients were included (186 NIH, 233 LUMC); 194 (46%) had MAS endocrinopathies. Median age at last follow-up was 30.2 years (range 3.2-84.6, interquartile range [IQR] 25.5), and median skeletal burden score was 16.6 (range 0-75, IQR 33). A total of 48 (59%) patients suffered one or more lifetime fracture (median 1, range 0-70, IQR 4). Median age at first fracture was 8 years (range 1-76, IQR 10). Fracture rates peaked between 6 and 10 years of age and decreased thereafter. Lifetime fracture rate was associated with skeletal burden score (β = 0.40, p < 0.01) and MAS hyperthyroidism (β = 0.22, p = 0.01). Younger age at first fracture was associated with skeletal burden score (β = -0.26, p = 0.01) and male sex (β = -0.23, p = 0.01). Both skeletal burden score >25 and age at first fracture ≤7 years were associated with a higher total number of lifetime fractures (median 4, range 1-70, IQR 5 versus median 1, range 1-13, IQR 1) (p < 0.01). In conclusion, higher skeletal burden score and MAS hyperthyroidism are associated with long-bone fractures in FD/MAS. Both skeletal burden score ≥25 and age at first fracture ≤7 years are associated with a higher lifetime long-bone fracture risk and may predict a more severe clinical course. These results may allow clinicians to identify FD/MAS patients at risk for severe disease who may be candidates for early therapeutic interventions. © 2021 American Society for Bone and Mineral Research (ASBMR). This article has been contributed to by US Government employees and their work is in the public domain in the USA.

Citing Articles

Incidence and Prevalence of Fibrous Dysplasia/McCune-Albright Syndrome: A Nationwide Registry-Based Study in Denmark.

Meier M, Vago E, Abrahamsen B, Dekkers O, Horvath-Puho E, Rejnmark L J Clin Endocrinol Metab. 2024; 109(6):1423-1432.

PMID: 38174586 PMC: 11099484. DOI: 10.1210/clinem/dgad744.


Serum Phosphorus as a Driver of Skeletal Morbidity in Fibrous Dysplasia.

Gun Z, Osamor 3rd C, Taylor J, Li X, Szymczuk V, Boyce A J Clin Endocrinol Metab. 2023; 109(5):1334-1340.

PMID: 37975816 PMC: 11031212. DOI: 10.1210/clinem/dgad671.


Phenotyping Pain in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.

Golden E, van der Heijden H, Ren B, Randall E, Drubach L, Shah N J Clin Endocrinol Metab. 2023; 109(3):771-782.

PMID: 37804088 PMC: 11491648. DOI: 10.1210/clinem/dgad589.

References
1.
Majoor B, Papapoulos S, Dijkstra P, Fiocco M, Hamdy N, Appelman-Dijkstra N . Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates. J Clin Endocrinol Metab. 2019; 104(12):6069-6078. DOI: 10.1210/jc.2018-02543. View

2.
Leet A, Chebli C, Kushner H, Chen C, Kelly M, Brillante B . Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res. 2004; 19(4):571-7. DOI: 10.1359/JBMR.0301262. View

3.
Valente M, Gonzalez O, Miocevic M, MacKinnon D . A Note on Testing Mediated Effects in Structural Equation Models: Reconciling Past and Current Research on the Performance of the Test of Joint Significance. Educ Psychol Meas. 2016; 76(6):889-911. PMC: 5098906. DOI: 10.1177/0013164415618992. View

4.
Kushchayeva Y, Kushchayev S, Glushko T, Tella S, Teytelboym O, Collins M . Fibrous dysplasia for radiologists: beyond ground glass bone matrix. Insights Imaging. 2018; 9(6):1035-1056. PMC: 6269335. DOI: 10.1007/s13244-018-0666-6. View

5.
Majoor B, Andela C, Bruggemann J, van de Sande M, Kaptein A, Hamdy N . Determinants of impaired quality of life in patients with fibrous dysplasia. Orphanet J Rare Dis. 2017; 12(1):80. PMC: 5408426. DOI: 10.1186/s13023-017-0629-x. View